Stoke Therapeutics (STOK) Other Operating Expenses (2019 - 2025)
Stoke Therapeutics' (STOK) quarterly Other Operating Expenses came in at $152.4 million in Q4 2025, up 439.1% quarter-over-quarter from -$44.9 million in Q2 2025.
Stoke Therapeutics (STOK) Other Operating Expenses (2019 - 2025) Analysis & Trends
Stoke Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $152.4 million for Q4 2025.
- On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $152.4 million in Q4 2025; TTM through Mar 2026 was $107.4 million, a 379.27% increase from a year earlier, with the FY2023 full-year figure at -$133.6 million, changed N/A from the prior year.
- Other Operating Expenses advanced to $152.4 million in Q4 2025 per STOK's latest filing, from -$44.9 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $152.4 million in Q4 2025 and bottomed at -$133.6 million in Q4 2023.
- The 3-year median for Other Operating Expenses is -$41.7 million (2024), against an average of -$16.2 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 152.37 Mn |
| Jun 30, 2025 | -44.93 Mn |
| Sep 30, 2024 | -38.47 Mn |
| Dec 31, 2023 | -133.63 Mn |
| Dec 31, 2019 | 1,000.00 |